
Nimish Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7622487/publications.pdf Version: 2024-02-01



Νιμιςή Ράτει

#	Article	IF	CITATIONS
1	Overcoming Past Perceptions and a Profession-Wide Identity Crisis to Reflect Pharmacy's Future. American Journal of Pharmaceutical Education, 2022, 86, 8829.	2.1	7
2	Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. British Journal of Haematology, 2022, 197, 63-70.	2.5	16
3	Method of Calculating Renal Function Estimates Could Inappropriately Exclude Transgender Patients Receiving Gender-Affirming Hormone Therapy from Pre-Exposure Prophylaxis Eligibility. LGBT Health, 2022, 9, 199-206.	3.4	1
4	Prevalence and Predictors of <i>Pseudomonas aeruginosa</i> Among Hospitalized Patients With Diabetic Foot Infections. Open Forum Infectious Diseases, 2022, 9, .	0.9	6
5	Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 1816-1822.e2.	1.5	82
6	Comparative effectiveness of earlyâ€ŧargeted use of fidaxomicin versus oral vancomycin among hospitalized veterans' affairs patients with infections due to Clostridioides difficile. Pharmacotherapy, 2021, 41, 212-219.	2.6	5
7	Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective. Antibiotics, 2021,	3.7	1
8	Early clinical trial data and realâ€world assessment of COVIDâ€19 vaccines: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2021, 41, 837-850.	2.6	6
9	US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. Open Forum Infectious Diseases, 2021, 8, ofab380.	0.9	3
10	Impact of a Plan of Care Protocol on Patient Outcomes in People Who Inject Drugs With Infective Endocarditis. Journal of Infectious Diseases, 2020, 222, S506-S512.	4.0	11
11	Effect of Vancomycin-Associated Acute Kidney Injury on Incidence of 30-Day Readmissions among Hospitalized Veterans Affairs Patients with Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	3
12	Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections. International Journal of Antimicrobial Agents, 2020, 56, 106210.	2.5	29
13	Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patients. Annals of Hepatology, 2019, 18, 601-606.	1.5	1
14	Short Communication: Relationship Between Contraindicated Drug–Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2019, 35, 430-433.	1.1	8
15	Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series. Antiviral Research, 2018, 152, 111-116.	4.1	5
16	Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. Journal of Antimicrobial Chemotherapy, 2018, 73, 2643-2651.	3.0	33
17	Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. Clinical Drug Investigation, 2018, 38, 935-943.	2.2	12
18	Analysis of drug–drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. American Journal of Health-System Pharmacy, 2018, 75, 1132-1139.	1.0	13

NIMISH PATEL

#	Article	IF	CITATIONS
19	Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Clinical Infectious Diseases, 2017, 64, ciw815.	5.8	61
20	Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
21	Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients. Annals of Pharmacotherapy, 2017, 51, 365-372.	1.9	21
22	Relationship between vancomycin tolerance and clinical outcomes in <i>Staphylococcus aureus</i> bacteraemia. Journal of Antimicrobial Chemotherapy, 2017, 72, 535-542.	3.0	34
23	Secular Trends in Nosocomial Vancomycin-Resistant Enterococcal Bloodstream Infections Among United States Veterans Affairs Hospitals, Fiscal Years 2004 through 2014. Infection Control and Hospital Epidemiology, 2017, 38, 1114-1116.	1.8	0
24	Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency Virus. AIDS Patient Care and STDs, 2017, 31, 370-376.	2.5	24
25	Reply to Chanderraj et al. Clinical Infectious Diseases, 2017, 65, 1427-1428.	5.8	Ο
26	Comparing the Population-Based Frequency of Contraindicated Drug-Drug Interactions Between Daclatasvir/Sofosbuvir (DAC/SOF), Grazoprevir/Elbasvir (GZR/EBV), Ledipasvir/Sofosbuvir (LDV/SOF), Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin (OMB/PTV/RTV + DSV ± RBV) and Simeprevir/Sofosbuvir (SIM/SOF) for Treatment of Hepatitis C Monoinfection. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
27	Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. Infectious Diseases and Therapy, 2016, 5, 299-312.	4.0	30
28	Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2016, 60, 3070-3075.	3.2	16
29	Universal precautions in Central Asia: the need for multiple strategies in this window of opportunity. Journal of Hospital Infection, 2015, 89, 197-201.	2.9	8
30	Prevalence of Drug–Drug Interactions upon Addition of Simeprevir- or Sofosbuvir-Containing Treatment to Medication Profiles of Patients with HIV and Hepatitis C Coinfection. AIDS Research and Human Retroviruses, 2015, 31, 189-197.	1.1	11
31	Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. Clinical Infectious Diseases, 2015, 61, 871-878.	5.8	110
32	A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. Infectious Diseases and Therapy, 2015, 4, 67-78.	4.0	17
33	Incidence and Clinical Predictors of Nonresponse to Hepatitis B Vaccination among Patients Receiving Hemodialysis: Importance of Obesity. Southern Medical Journal, 2015, 108, 567-573.	0.7	10
34	Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. Infectious Diseases and Therapy, 2014, 3, 225-233.	4.0	14
35	Predicting the Probability of Experiencing Clinically Significant Drug–Drug Interactions Involving Boceprevir-Containing Hepatitis C Therapy Among Patients Coinfected with Hepatitis C and HIV. AIDS Patient Care and STDs, 2014, 28, 513-516.	2.5	1
36	Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus. Journal of Pharmacy Technology, 2014, 30, 159-167.	1.0	3

NIMISH PATEL

#	Article	lF	CITATIONS
37	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 4252-4259.	3.2	68
38	Comparative Evaluation of Serotonin Toxicity among Veterans Affairs Patients Receiving Linezolid and Vancomycin. Antimicrobial Agents and Chemotherapy, 2013, 57, 5901-5911.	3.2	10
39	Daptomycin Pharmacokinetics and Pharmacodynamics in a Pooled Sample of Patients Receiving Thrice-Weekly Hemodialysis. Antimicrobial Agents and Chemotherapy, 2013, 57, 864-872.	3.2	21
40	Frequency of electrocardiogram testing among <scp>HIV</scp> â€infected patients at risk for medicationâ€induced <scp>QTc</scp> prolongation. HIV Medicine, 2013, 14, 463-471.	2.2	9
41	A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. Journal of Antimicrobial Chemotherapy, 2012, 67, 727-735.	3.0	25
42	Defining the pharmacist role in the pandemic outbreak of novel H1N1 influenza. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 763-767.	1.5	44
43	New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. HIV/AIDS - Research and Palliative Care, 2012, 4, 61.	0.8	4
44	Use of Pharmacokinetic and Pharmacodynamic Principles To Determine Optimal Administration of Daptomycin in Patients Receiving Standardized Thrice-Weekly Hemodialysis. Antimicrobial Agents and Chemotherapy, 2011, 55, 1677-1683.	3.2	33
45	Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2011, 66, 1600-1608.	3.0	59
46	Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding. Antimicrobial Agents and Chemotherapy, 2011, 55, 4277-4282.	3.2	69
47	Vancomycin: We Can't Get There From Here. Clinical Infectious Diseases, 2011, 52, 969-974.	5.8	214
48	Pharmacokinetics and Pharmacodynamics of Intravenous Daptomycin during Continuous Ambulatory Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1081-1088.	4.5	27
49	Predictors of Clinically Significant Drug-Drug Interactions Among Patients Treated with Nonnucleoside Reverse Transcriptase Inhibitor–, Protease Inhibitor–, and Raltegravir-Based Antiretroviral Regimens. Annals of Pharmacotherapy, 2011, 45, 317-324.	1.9	48
50	Rilpivirine: A new addition to the anti-HIV-1 armamentarium. Drugs of Today, 2011, 47, 5.	1.1	21
51	Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents. Annals of Pharmacotherapy, 2010, 44, 157-165.	1.9	67
52	Identification of Optimal Renal Dosage Adjustments for Traditional and Extended-Infusion Piperacillin-Tazobactam Dosing Regimens in Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 460-465.	3.2	52
53	Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. Journal of Antimicrobial Chemotherapy, 2010, 65, 2285-2290.	3.0	35
54	Correlation between Vancomycin MIC Values and Those of Other Agents against Gram-Positive Bacteria among Patients with Bloodstream Infections Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> . Antimicrobial Agents and Chemotherapy, 2009, 53, 5141-5144.	3.2	33

NIMISH PATEL

#	Article	IF	CITATIONS
55	Relationship between Initial Vancomycin Concentrationâ€īime Profile and Nephrotoxicity among Hospitalized Patients. Clinical Infectious Diseases, 2009, 49, 507-514.	5.8	501
56	Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagnostic Microbiology and Infectious Disease, 2009, 64, 236-240.	1.8	64
57	The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic Shock. American Journal of Therapeutics, 2009, 16, 508-511.	0.9	75
58	Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagnostic Microbiology and Infectious Disease, 2008, 61, 96-102.	1.8	30
59	Relationship between Various Definitions of Prior Antibiotic Exposure and Piperacillin-Tazobactam Resistance among Patients with Respiratory Tract Infections Caused by <i>Pseudomonas aeruginosa</i> . Antimicrobial Agents and Chemotherapy, 2008, 52, 2933-2936.	3.2	14
60	Reimbursement for clinical services. American Journal of Health-System Pharmacy, 2007, 64, 926-926.	1.0	0
61	Predictors of 30-Day Mortality among Patients with <i>Pseudomonas aeruginosa</i> Bloodstream Infections: Impact of Delayed Appropriate Antibiotic Selection. Antimicrobial Agents and Chemotherapy, 2007, 51, 3510-3515.	3.2	279
62	Identification of Patients With <i>Pseudomonas aeruginosa</i> Respiratory Tract Infections at Greatest Risk of Infection With Carbapenem-Resistant Isolates. Infection Control and Hospital Epidemiology, 2007, 28, 959-965.	1.8	24